Enzon Pharmaceuticals, Inc. has started an exchange offer for its Series C Non-Convertible Redeemable Preferred Stock, in connection with a merger with Viskase Companies, Inc. Holders of Series C Preferred Stock can exchange their shares for Enzon’s common stock at a specific rate until February 27, 2026. The Offer details are outlined in documents filed with the U.S. Securities and Exchange Commission on January 28 and 30, 2026. Investors can access these documents through the SEC website or by contacting the appointed agents. Enzon Pharmaceuticals, Inc. is a public company acquisition platform. No recommendations are made on participating in the Offer.

Read more at GlobeNewswire: Enzon Announces Commencement of Exchange Offer Relating to